The Europe C-Reactive Protein Testing Market should witness market growth of 2.6% CAGR during the forecast period (2023-2030).
The increased number of chronic diseases such as diabetes, cardiovascular disease, cancer, inflammatory bowel disease, and arthritis in the general population is one of the key reasons driving the market. The possibility of effective therapy is increased when chronic disorders are discovered early. In order to avoid spending a lot of money on costly treatments, healthcare providers constantly promote early detection of clinical illnesses. Furthermore, expanding several initiatives by governments, nonprofit organizations, and major market participants to raise awareness is crucial in further boosting the growth of the market.
Rapid kits and other point-of-care devices are also readily available, contributing to the market's expansion. Further, it reduces medical professionals' responsibilities by removing demands for specimen collection and inspection from regional laboratories. Thus, during the projected period, major market players should have plenty of possibilities to participate in and contribute to the market's growth as a result of the development of such special test kits.
According to the UK government's "Future of an Ageing Population" report, by 2040, the UK is expected to have roughly one in seven individuals over 75. There will be 1.42 million more residents with a head of household over 85 or older by 2037, an increase of 161% over the previous 25 years. Over 5.5 million individuals will be added to the working-age population between 50 and the state pension age (SPA), from 26% in 2012 to 34% in 2050. In 2012, there were 15 million people in France over 60. In 2060, this number will increase to 24 million. Due to the increased risk of noncommunicable diseases among the aging population in European countries, market participants are expected to experience growth in the coming years.
The Germany market dominated the Europe C-reactive Protein Testing Market by Country in 2022 and would continue to be a dominant market till 2030; thereby, achieving a market value of $236.1 million by 2030. The UK market is estimated to grow at a CAGR of 1.7% during (2023-2030). Additionally, The France market would exhibit a CAGR of 3.3% during (2023-2030).
Based on Application, the market is segmented into Cardiovascular Disease, Inflammatory Bowel Disease, Rheumatoid Arthritis, Diabetes, and Others. Based on Assay Type, the market is segmented into Immunoturbidimetric Assays, Enzyme-linked Immunosorbent Assay (ELISA), Chemiluminescence Immunoassay (CLIA), and Others. Based on End-user, the market is segmented into Hospitals & Clinics, Diagnostic Laboratories, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Danaher Corporation, F. Hoffmann-La Roche Ltd., Abbott Laboratories, Laboratory Corporation of America Holdings, Randox Laboratories Limited, Thermo Fisher Scientific Inc., Quest Diagnostics Incorporated, Horiba, Ltd., Merck KGaA, and Zoetis, Inc.
The increased number of chronic diseases such as diabetes, cardiovascular disease, cancer, inflammatory bowel disease, and arthritis in the general population is one of the key reasons driving the market. The possibility of effective therapy is increased when chronic disorders are discovered early. In order to avoid spending a lot of money on costly treatments, healthcare providers constantly promote early detection of clinical illnesses. Furthermore, expanding several initiatives by governments, nonprofit organizations, and major market participants to raise awareness is crucial in further boosting the growth of the market.
Rapid kits and other point-of-care devices are also readily available, contributing to the market's expansion. Further, it reduces medical professionals' responsibilities by removing demands for specimen collection and inspection from regional laboratories. Thus, during the projected period, major market players should have plenty of possibilities to participate in and contribute to the market's growth as a result of the development of such special test kits.
According to the UK government's "Future of an Ageing Population" report, by 2040, the UK is expected to have roughly one in seven individuals over 75. There will be 1.42 million more residents with a head of household over 85 or older by 2037, an increase of 161% over the previous 25 years. Over 5.5 million individuals will be added to the working-age population between 50 and the state pension age (SPA), from 26% in 2012 to 34% in 2050. In 2012, there were 15 million people in France over 60. In 2060, this number will increase to 24 million. Due to the increased risk of noncommunicable diseases among the aging population in European countries, market participants are expected to experience growth in the coming years.
The Germany market dominated the Europe C-reactive Protein Testing Market by Country in 2022 and would continue to be a dominant market till 2030; thereby, achieving a market value of $236.1 million by 2030. The UK market is estimated to grow at a CAGR of 1.7% during (2023-2030). Additionally, The France market would exhibit a CAGR of 3.3% during (2023-2030).
Based on Application, the market is segmented into Cardiovascular Disease, Inflammatory Bowel Disease, Rheumatoid Arthritis, Diabetes, and Others. Based on Assay Type, the market is segmented into Immunoturbidimetric Assays, Enzyme-linked Immunosorbent Assay (ELISA), Chemiluminescence Immunoassay (CLIA), and Others. Based on End-user, the market is segmented into Hospitals & Clinics, Diagnostic Laboratories, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Danaher Corporation, F. Hoffmann-La Roche Ltd., Abbott Laboratories, Laboratory Corporation of America Holdings, Randox Laboratories Limited, Thermo Fisher Scientific Inc., Quest Diagnostics Incorporated, Horiba, Ltd., Merck KGaA, and Zoetis, Inc.
Scope of the Study
By Application
- Cardiovascular Disease
- Inflammatory Bowel Disease
- Rheumatoid Arthritis
- Diabetes
- Others
By Assay Type
- Immunoturbidimetric Assays
- Enzyme-linked Immunosorbent Assay (ELISA)
- Chemiluminescence Immunoassay (CLIA)
- Others
By End-user
- Hospitals & Clinics
- Diagnostic Laboratories
- Others
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- Danaher Corporation
- F. Hoffmann-La Roche Ltd
- Abbott Laboratories
- Laboratory Corporation of America Holdings
- Randox Laboratories Limited
- Thermo Fisher Scientific Inc.
- Quest Diagnostics Incorporated
- Horiba, Ltd.
- Merck KGaA
- Zoetis, Inc.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. Europe C-reactive Protein Testing Market by Application
Chapter 5. Europe C-reactive Protein Testing Market by Assay Type
Chapter 6. Europe C-reactive Protein Testing Market by End User
Chapter 7. Europe C-reactive Protein Testing Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- Danaher Corporation
- F. Hoffmann-La Roche Ltd
- Abbott Laboratories
- Laboratory Corporation of America Holdings
- Randox Laboratories Limited
- Thermo Fisher Scientific Inc.
- Quest Diagnostics Incorporated
- Horiba, Ltd.
- Merck KGaA
- Zoetis, Inc.
Methodology
LOADING...
